


APPLICANTS: Tamer et al.
U.S.S.N.: 09/813,432

to claims 1 and 2 can be found in claims 1 and 2 as originally filed. Support for new claims 44-48 can be found at, *e.g.*, page 2, lines 21-26; and page 85, line 19 to page 87, line 5. No new matter has been added by these amendments.

Applicants submit that new claims 44-48 are linking claims whose inclusion with the claims of Group I is acceptable under In Re Ochiai and In Re Brouwer (*See* Official Gazette, March 26, 1996, establishing guidelines for treatment of product and process claims). Linking claims permit joinder of claims relating to the making of a novel product or the use of a novel composition with the method of making the product or using the composition. In the present case, claims 44-48 use the novel nucleic acids of group II in a method of making the novel polypeptides of group I.

A petition for a one-month extension of time is filed herewith. With this extension, a response is due on August 21, 2002. The Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Attorney Reference No: 15966-729 (Cura-229). Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,




Ivor R. Elrifi (Reg. No. 39,529)
Naomi Biswas (Reg. No. 38,384)
Attorneys for the Applicant
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

APPLICANTS:

T. [redacted] et al.

JCTAS S.N.:

09/813,432



VERSION WITH MARKINGS TO SHOW CHANGES MADE

RECEIVED
AUG 26 2002
TECH CENTER 1600/2900

In the claims:

Claims 1 and 2 have been amended as follows:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - a) a mature form of [the amino acid sequence selected from the group consisting of] SEQ ID NO: [2, 4, 6, 8, 10, 12, 14, 16, 18, 20,] 22 [or 24];
 - b) a variant of a mature form of [the amino acid sequence selected from the group consisting of] SEQ ID NO: [2, 4, 6, 8, 10, 12, 14, 16, 18, 20,] 22 [or 24], wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
 - c) the amino acid sequence [selected from the group consisting] of SEQ ID NO: [2, 4, 6, 8, 10, 12, 14, 16, 18, 20,] 22 [or 24];
 - d) a variant of the amino acid sequence [selected from the group consisting] of SEQ ID NO: [2, 4, 6, 8, 10, 12, 14, 16, 18, 20,] 22 [or 24] wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and
 - e) a fragment of any of a) through d).
2. The polypeptide of claim 1 that is a naturally occurring allelic variant of [the sequence selected from the group consisting of.]SEQ ID NO: [2, 4, 6, 8, 10, 12, 14, 16, 18, 20,] 22 [or 24].

Claims 5-28, 30-31 and 33-43 have been cancelled.

New claims 44-48 have been added:

APPLICANTS:
U.S.S.N.:

T. [REDACTED] et al.
09/813,432

44. (New) A method of producing the polypeptide of claim 1, the method comprising culturing a cell under conditions that lead to expression of the polypeptide, wherein said cell comprises a vector comprising an isolated nucleic acid molecule comprising SEQ ID NO: 22.

BS 45. (New) The method of claim 44 wherein the cell is a bacterial cell.

46. (New) The method of claim 44 wherein the cell is an insect cell.

47. (New) The method of claim 44 wherein the cell is a yeast cell.

48. (New) The method of claim 44 wherein the cell is a mammalian cell.

TRA 1703407v1